Coronavirus (COVID-19) Collection
Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19The deleterious impact of the hyperactive immune response triggered by SARS-CoV-2 has been reported since the start of the pandemic (Giamarellos-Bourboulis et al., 2020, Vabret et al., 2020). Therapeutic immunomodulation emerged as a potentially life-saving option for patients with severe COVID-19 (Luis et al., 2021). Available drugs inhibiting the pleiotropic proinflammatory cytokine interleukin 6 (IL-6) rapidly became of particular interest because elevated IL-6 levels seemed to mediate systemic inflammatory responses associated with SARS-CoV-2 infection and the development of acute respiratory distress syndrome (ARDS) and multiorgan failure (McGonagle et al., 2020).
Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective studySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), is a novel beta-coronavirus first identified in December 2019 in Wuhan, China (Huang et al., 2020). Most cases of SARS-CoV-2 infection have a mild-to-moderate course, although a significant proportion of patients will ultimately develop acute respiratory distress syndrome (ARDS) (Wang et al., 2020), which carries a high mortality rate (Wu et al., 2020). Older age has been consistently identified as a risk factor for death and poor outcomes in COVID-19.
Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative studyAs of January 2021, the worldwide outbreak of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), responsible of the viral pneumonia known as COVID-19, has caused more than 94 million infections and 2 million deaths (Johns Hopkins University of Medicine, 2021). SARS-CoV-2 infection produces mild symptoms of respiratory tract infection in most individuals; however, a subgroup of patients with COVID-19 develop severe disease, with acute respiratory distress syndrome (ARDS) and/or multiple organ dysfunction especially affecting the heart, liver and kidneys.